Wegovy Average Weight Loss: Clinical Trial Evidence

Clinically Proven UK Registered Pharmacy

Wegovy Average Weight Loss: Clinical Trial Evidence

UK-registered clinical team
Confidential and secure
No GP visit needed
Fast and discreet delivery
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £10 off for new customers
Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment
£89.00 From £79.00 £10 discount using discount code Weightlossnew
LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £135.00

£36.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £169.00

£44.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £210.00

£55.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £235.00

£61.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £260.00

£67.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £277.00

£71.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £79.00

£22.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £99.00

£27.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £109.00

£29.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £159.00

£42.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £189.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation

Wegovy Average Weight Loss: Clinical Trial Evidence

Understanding wegovy average weight loss results from clinical trials helps set realistic expectations before starting treatment. In the landmark STEP trials, participants achieved an average 15-17% body weight reduction over 68 weeks with semaglutide 2.4mg—the active ingredient in Wegovy [1]. At Cured Pharmacy, our UK-registered clinical team provides evidence-based weight loss treatment with transparent pricing from £79.00, subject to prescriber approval.

STEP Trial Results: What the Clinical Evidence Shows

The STEP (Semaglutide Treatment Effect in People with obesity) programme represents the most comprehensive clinical evidence for Wegovy's efficacy. STEP 1, the pivotal trial involving 1,961 adults with obesity, demonstrated that participants receiving semaglutide 2.4mg lost an average of 14.9% of their baseline body weight over 68 weeks, compared to 2.4% in the placebo group [1].

More impressively, 86.4% of participants on Wegovy achieved at least 5% weight loss—the threshold considered clinically meaningful by NICE—whilst 69.1% lost 10% or more, and 50.5% achieved 15% or greater weight reduction [1]. These results established semaglutide as one of the most effective pharmacological weight loss interventions licensed in the UK.

STEP 2 examined patients with type 2 diabetes, showing an average 9.6% weight loss over 68 weeks [2]. Whilst lower than STEP 1, this still represented significant clinical benefit for a population historically difficult to treat. The MHRA licensed Wegovy based on this robust trial data, confirming its efficacy and safety profile for UK patients.

How Wegovy Produces Weight Loss: The Mechanism

Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a natural gut hormone released after eating. By activating GLP-1 receptors in the brain's appetite centres, semaglutide reduces hunger signals and increases feelings of fullness, making it easier to maintain a reduced-calorie diet [3].

Unlike older weight loss medications that work peripherally, semaglutide acts on central nervous system pathways that regulate food intake and energy expenditure. This dual action—reducing appetite whilst slowing gastric emptying—creates a powerful physiological environment for sustained weight reduction when combined with lifestyle modifications [3].

The once-weekly subcutaneous injection delivers consistent therapeutic levels throughout the week, with dose escalation over 16-20 weeks minimising gastrointestinal side effects whilst optimising efficacy. Your UK prescriber will determine the appropriate titration schedule based on your individual response and tolerability.

Why Weekly Injections Work Better

Semaglutide's molecular structure allows for prolonged activity, maintaining therapeutic levels for seven days after a single injection. This pharmacokinetic profile improves adherence compared to daily treatments, with clinical trials showing 84% of participants completing the full 68-week STEP 1 protocol [1]. Better adherence translates directly to better weight loss outcomes in real-world settings.

Realistic Weight Loss Expectations: Individual Variation

Whilst clinical trials report average outcomes, individual results vary considerably based on baseline BMI, adherence to lifestyle modifications, metabolic health, and genetic factors. In STEP 1, weight loss ranged from minimal response to over 25% body weight reduction in the highest responders [1].

Patients with higher baseline BMI typically achieve greater absolute weight loss but similar percentage reductions. A 100kg patient losing 15% would lose 15kg, whilst a 70kg patient losing 15% would lose 10.5kg—both clinically significant outcomes that reduce obesity-related health risks.

Your UK prescriber will discuss realistic goals during your consultation. Most patients begin noticing appetite reduction within the first 2-4 weeks, with measurable weight loss typically evident by week 8-12. Maximum effects usually occur between months 6-12, with weight maintenance strategies then becoming the focus [4].

Factors That Influence Your Results

Dietary adherence, physical activity levels, sleep quality, stress management, and underlying metabolic conditions all influence Wegovy's effectiveness. Clinical trials required participants to follow a reduced-calorie diet and increase physical activity—medication alone, without lifestyle changes, produces suboptimal results. Our clinical team provides guidance on optimising these factors during your treatment journey.

Treatment Active Ingredient Average Weight Loss Trial Duration Starting Price
Wegovy Semaglutide 2.4mg 15-17% body weight 68 weeks From £89.00
Saxenda Liraglutide 3.0mg 8-9% body weight 56 weeks From £68.00
Mounjaro Tirzepatide (dual agonist) 15-22% body weight 72 weeks From £145.00

Wegovy Dosing Schedule and Weight Loss Timeline

Wegovy treatment follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst building to the therapeutic 2.4mg maintenance dose. The standard UK titration schedule begins at 0.25mg weekly for four weeks, increasing monthly through 0.5mg, 1.0mg, and 1.7mg, before reaching 2.4mg at week 17 [5].

This gradual escalation allows your digestive system to adapt to semaglutide's effects on gastric emptying. Patients who experience persistent nausea or vomiting may remain at a lower dose for an additional four weeks before advancing—your prescriber will adjust the schedule based on your individual tolerability.

Weight loss typically begins during the escalation phase, with most patients losing 2-4% body weight by week 16. The majority of total weight loss occurs between weeks 20-60, with weight stabilisation usually achieved by week 68 [1]. Continued treatment helps maintain weight loss, with STEP 4 demonstrating significant weight regain after discontinuation [6].

Comparing Wegovy to Other Weight Loss Treatments

Wegovy represents a significant advancement over earlier pharmacological options. Compared to orlistat (which blocks fat absorption and produces average 3-5% weight loss), semaglutide's 15-17% average reduction offers substantially greater efficacy [7]. Older appetite suppressants like phentermine carry cardiovascular risks that limited their use, whilst Wegovy demonstrated cardiovascular safety in the SELECT trial [8].

Newer dual-agonist treatments targeting both GLP-1 and GIP receptors have shown even greater weight loss in clinical trials, with some patients achieving over 20% reduction. However, these remain more expensive and less widely available in the UK market. For most patients, Wegovy offers an optimal balance of efficacy, safety, cost, and accessibility.

Surgical interventions like gastric bypass produce greater weight loss (25-35%) but carry procedural risks and require lifelong dietary restrictions. NICE guidelines recommend considering pharmacological treatment before surgery for patients meeting eligibility criteria. Your UK prescriber can discuss which approach best suits your clinical situation and weight loss goals.

When to Consider Alternative Treatments

Patients with contraindications to GLP-1 agonists (including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2) require alternative approaches. Those with primarily emotional or binge eating patterns may benefit from psychological interventions alongside or instead of medication. Your prescriber will assess your full medical history to determine the most appropriate treatment pathway.

Starting Wegovy Treatment at Cured Pharmacy

At Cured Pharmacy, accessing Wegovy begins with a free online consultation completed in under three minutes. Our UK-registered prescribers (supervised by Superintendent Pharmacist Tarun Kumar, GPhC 2233073) review your medical history, current medications, and weight loss goals to determine eligibility and safety.

Wegovy is licensed for adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. Treatment should be discontinued if patients fail to lose at least 5% of initial body weight after 12 weeks at the maintenance dose, as per MHRA guidance [5].

Once approved, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) with discreet packaging and delivery. We provide transparent upfront pricing from £79.00 per pen—lower than typical market rates—with no hidden consultation fees. All medications are genuine UK-licensed products sourced through regulated supply chains, ensuring quality and safety.

Ongoing Clinical Support

Weight loss treatment requires ongoing monitoring for efficacy and side effects. Our clinical team remains available throughout your treatment journey to adjust dosing, manage adverse effects, and provide lifestyle guidance. Regular follow-up assessments ensure treatment remains appropriate and effective, with the option to pause, adjust, or discontinue based on your individual response and changing clinical needs.

Scientific References

  1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
  2. Davies, M., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
  3. Müller, T. D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
  4. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
  5. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799
  6. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
  7. Khera, R., et al. (2016). Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 315(22), 2424–2434. https://doi.org/10.1001/jama.2016.7602
  8. Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual weight loss results may vary based on adherence to lifestyle modifications, baseline health status, and metabolic factors. Wegovy is not suitable for everyone—your prescriber will assess your eligibility and monitor your treatment for safety and efficacy.

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

What is the average weight loss with Wegovy in clinical trials?
In the STEP 1 trial, participants lost an average of 14.9% of their baseline body weight over 68 weeks, with 50.5% achieving 15% or greater weight reduction. Individual results vary based on adherence to lifestyle modifications and metabolic factors.
How long does it take to see wegovy average weight loss results?
Most patients notice appetite reduction within 2-4 weeks and measurable weight loss by weeks 8-12. The majority of total weight loss occurs between weeks 20-60, with maximum effects typically achieved by 68 weeks of continuous treatment.
Do you regain weight after stopping Wegovy?
The STEP 4 trial showed participants regained approximately two-thirds of lost weight within one year of discontinuation. Continued treatment appears necessary to maintain weight loss, though lifestyle modifications can help minimise regain.
Is Wegovy more effective than other weight loss medications?
Wegovy produces significantly greater weight loss than older options like orlistat (15-17% vs 3-5% average reduction). Newer dual-agonist treatments show comparable or slightly higher efficacy in clinical trials, though with higher costs and less availability in the UK.
What percentage of people lose weight on Wegovy?
In STEP 1, 86.4% of participants achieved at least 5% weight loss (the clinically meaningful threshold), 69.1% lost 10% or more, and 50.5% achieved 15% or greater reduction over 68 weeks.
Can I get Wegovy from Cured Pharmacy if I don't meet NHS criteria?
Wegovy requires a prescription from a UK-registered prescriber who will assess your eligibility based on MHRA licensing criteria (BMI ≥30 or BMI ≥27 with comorbidities). Our clinical team applies the same safety standards regardless of NHS availability, ensuring appropriate prescribing.
How much does Wegovy cost at Cured Pharmacy?
Wegovy starts from £79.00 per pen at Cured Pharmacy, with transparent upfront pricing shown before your free consultation. Final cost depends on your prescribed dose, which your UK prescriber determines based on the standard titration schedule.
Are wegovy weight loss clinical trial results achievable in real-world use?
Real-world studies show slightly lower average weight loss than controlled trials (typically 10-12% vs 15-17%), primarily due to adherence challenges and less intensive lifestyle support. However, many patients still achieve clinically significant results with proper adherence and ongoing clinical monitoring.